CClinicalTrials.gg
CompletedNCT02834065Updated Feb 24, 2023

Cognitive Effects of Body Temperature During Hypothermic Circulatory Arrest

An interventional study of Cardiopulmonary bypass machine in Cognition Disorders, sponsored by Duke University. Completed at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-24.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
273
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

In this study the investigator will randomize 273 subjects to deep (\<20°C), low (20.1°C-24°C), or moderate (24.1°C-28°C) hypothermia during aortic arch surgery with circulatory arrest. The primary purpose of this study is to determine the effect of deep vs low vs moderate hypothermia on neurocognitive function, brain functional connectivity, and leukocyte SUMOylation patterns after surgical circulatory arrest in participants.

Read the detailed description

Purpose of the Study: Determine the effect of deep vs low vs moderate hypothermia on neurocognitive function, brain functional connectivity, and leukocyte SUMOylation patterns after surgical circulatory arrest.

Hypothesis: Deep hypothermia is superior to moderate hypothermia in reducing postoperative cognitive decline and preserving brain functional connectivity and that low hypothermia is non-inferior to deep hypothermia.

Design and Procedures: 273 informed and consenting patients who are scheduled for elective proximal aortic reconstructive surgery (ascending aorta + aortic valve or root) with concomitant proximal hemi- or total arch replacement via median sternotomy will be randomized to deep (\<20°C), low (20.1°C-24°C), or moderate (24.1°C-28°C) hypothermia during circulatory arrest. Cognitive testing using a standard battery will occur preoperatively (baseline), at 4 weeks, and at 1 year after surgery. Neuroimaging procedures before surgery, and at 4 weeks and 1 year after surgery will consist of high-resolution anatomic, resting-state fMRI (rs-fMRI) and magnetic resonance spectroscopy (MRS) sequences. To characterize leukocyte activation, whole blood will be drawn at 5 time points: at baseline (prior to surgery), before circulatory arrest, 10 minutes after reperfusion, 10 minutes after CPB, and 4 hours after CPB.

02

Conditions studied

  • Cognition Disorders

Keywords

  • Postoperative Cognitive Decline
  • Deep Hypothermic Circulatory Arrest
  • Cardiovascular Surgical Procedures
  • Functional Magnetic Resonance Imaging
  • Small Ubiquitin-Related Modifier Proteins
03

In context

Hypothermia

499 studies on the registry are indexed under Hypothermia; 53 are open to participants now.

This study's enrollment of 273 is above the median of 80 across 350 interventional studies indexed under Hypothermia.

Browse Hypothermia studies →

Lead sponsor

Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.

Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who are scheduled for elective proximal aortic reconstructive surgery (ascending aorta + aortic valve or root) with concomitant proximal hemi- or total arch replacement via median sternotomy

Exclusion criteria

Exclusion Criteria:

  • \< 18 years of age
  • History of symptomatic cerebrovascular disease, eg, prior stroke with residual deficit
  • Alcoholism (> 2 drinks/day)
  • Psychiatric illness (any clinical diagnoses requiring therapy)
  • Drug abuse (any illicit drug use in the past 3 months)
  • Hepatic insufficiency (liver function tests > 1.5 times the upper limit of normal)
  • Severe pulmonary insufficiency (requiring home oxygen therapy)
  • Renal failure (serum creatinine > 2.0 mg/dL)
  • Claustrophobic fear
  • Unable to read and thus unable to complete the cognitive testing
  • Pregnant women
  • Patients who score \< 24 on a baseline Mini Mental State Examination (MMSE) or ≥ 27 on the baseline Center for Epidemiological Studies Depression (CES-D) scale
  • Patients who have pre-existing unsafe implants for 3 Tesla magnetic resonance imaging (MRI).
  • Patients who have received chemotherapy in the last 12 months.
  • Patients with COVID-19 diagnosis within the past 12 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
273 participants (actual)

Study arms

  • Active comparator
    Deep Hypothermia

    Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature ≤20 degrees Celsius

    Device: Cardiopulmonary bypass machine

  • Active comparator
    Low Hypothermia

    Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 20.1 - 24.0 degrees Celsius

    Device: Cardiopulmonary bypass machine

  • Active comparator
    Moderate Hypothermia

    Initiation of circulatory arrest using the cardiopulmonary bypass machine at temperature 24.1 - 28 degrees Celsius

    Device: Cardiopulmonary bypass machine

Interventions

  • DeviceCardiopulmonary bypass machine

    Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest

06

What researchers measure

Primary outcomes

  1. Change in short-term cognition as measured by continuous cognitive score

    To characterize cognitive function over time while minimizing potential redundancy in the cognitive measures, a factor analysis will be performed on the cognitive test scores from baseline. A continuous change score will be calculated by subtracting the baseline cognitive index (the mean of the domain scores from factor analysis) from the follow-up cognitive index at 4 weeks.

    Time frame: From baseline to 4 weeks post-operatively

Secondary outcomes

  1. Change in SUMO 2/3 levels

    Time frame: Pre-incision, before circulatory arrest, 10 minutes after reperfusion, 10 minutes after cardiopulmonary bypass, 4 hrs after cardiopulmonary bypass

  2. Change in long-term cognition as measured by continuous cognitive score

    To characterize cognitive function over time while minimizing potential redundancy in the cognitive measures, a factor analysis will be performed on the cognitive test scores from baseline. A continuous change score will be calculated by subtracting the baseline cognitive index (the mean of the domain scores from factor analysis) from the follow-up cognitive index at 1 year.

    Time frame: From baseline to 1 year post-operatively

  3. Incidence of delirium

    Confusion Assessment Method (CAM)

    Time frame: Up to post-operative day 3

  4. Change in neurological function as measured by NIHSS

    Time frame: Assessed at baseline, post-op day 4, 4 weeks

  5. Change in neuronal metabolism

    Magnetic resonance spectra (metabolic peaks) of myoinositol, creatine, choline and N-acetyl aspartate

    Time frame: From baseline to 4 weeks

  6. Change in resting-state functional connectivity

    For the rs-fMRI data, the analyses of primary interest will be the spontaneous, low-frequency fluctuations in the blood oxygen level dependent (BOLD) data of the Default Mode, Salience, and Executive Control Networks.

    Time frame: From baseline to 4 weeks post-operatively

  7. Change in Duke Activity Status Index score

    Time frame: From baseline to 4 weeks postoperatively

  8. Change in depression score

    Measured by the Center for Epidemiological Studies Depression Scale (CES-D).

    Time frame: From baseline to 4 weeks postoperatively

  9. Change in anxiety score

    Measured by State Trait Anxiety Inventory (STA-I).

    Time frame: From baseline to 4 weeks postoperatively

  10. Change in SF-36 score

    Time frame: From baseline to 1 year postoperatively

  11. Change in employment status

    Time frame: From baseline to 1 year postoperatively

07

Study locations

4 sites
  • Emory Saint Joseph's Hospital
    Atlanta, Georgia 30342, United States
  • Duke University Health System
    Durham, North Carolina 27710, United States
  • Penn Presbyterian Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Baylor Scott & White Research Institute
    Plano, Texas 75093, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02834065
Lead sponsor
Duke University
Collaborators
Emory Healthcare, University of Pennsylvania, National Institutes of Health (NIH), Baylor Scott and White Health, National Heart, Lung, and Blood Institute (NHLBI)
Responsible party
Sponsor
First posted
Jul 15, 2016
Start date
Jul 28, 2016
Primary completion
Jan 2022
Completion
Feb 2023
Last update
Feb 24, 2023

Study contacts

Joseph P Mathew, MD, MHSc, MBA
principal investigator · Duke Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion